Advertisement

Management of Clinical Stage I (CSI) Disease in Testicular Cancer

  • Susanne Krege
Living reference work entry

Abstract

Though imaging does not give any hint to metastases, clinical stage I testis cancer patients might harbor micrometastases within the retroperitoneal lymph nodes. For this reason it was standard to offer adjuvant treatment at least to patients with a high risk for occult metastases. In seminoma a tumor size >4 cm and a rete testis infiltration were identified as risk factors; in nonseminoma it was vascular invasion. High-risk seminoma patients received adjuvant radiation of the paraaortal/paracaval region. Later, one course of carboplatinum became the favored option as application was short and with few side effects. Radiotherapy also became unattractive after reports about an increase of secondary malignancies in the long term. Recent data showed a decrease of recurrences (15–20% in case of high risk and 2–3% in case of low risk) even without adjuvant treatment, while recent publications about carboplatinum report about a 9–10% relapse rate in the long term. Therefore actually it is discussed to recommend surveillance for all clinical stage I seminoma patients.

Risk-adapted treatment in clinical stage I nonseminoma offered one course of PEB chemotherapy to high-risk patients with 30–50% occult metastases and recommended surveillance for low-risk patients with 10–15% micrometastases. As large series from Canada and the northern European countries reported excellent survival data also for high-risk patients under surveillance, the latter is discussed as general recommendation for all clinical stage I nonseminoma patients. Another argument for such a recommendation is long-term toxicity of polychemotherapy, especially cardiovascular events.

References

  1. Albers P, Siener R, Kliesch S, et al. Risk factors for relapse in clinical stage I nonseminomatous testicular germ cell tumors: results of the German Testicular Cancer Study Group Trial. J Clin Oncol. 2003;21:1505–12.CrossRefPubMedGoogle Scholar
  2. Albers P, Siener R, Krege S, et al. Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group. J Clin Oncol. 2008;26:2966–72.CrossRefPubMedGoogle Scholar
  3. Aparicio J, Maroto P, del Muro XG, et al. Risk-adapted treatment in clinical stage I testicular seminoma: the third Spanish Germ Cell Cancer Group study. J Clin Oncol. 2011;29:4677–81.CrossRefPubMedGoogle Scholar
  4. Cohn-Cedermark G, Stahl O, Tandstad T. Surveillance vs. adjuvant therapy of clinical stage I testicular tumors – a review and the SWENOTECA experience. Andrology. 2015;3:102–10.CrossRefPubMedGoogle Scholar
  5. Daugaard G, Gundgaard MG, Mortensen MS, et al. Surveillance for stage I nonseminoma testicular cancer: outcomes and long-term follow-up in a population-based cohort. J Clin Oncol. 2014;32:3817–23.CrossRefPubMedGoogle Scholar
  6. Dieckmann KP, Dralle-Filiz I, Matthies C, et al. Testicular seminoma clinical stage 1: treatment outcome on a routine care level. J Cancer Res Clin Oncol. 2016;142:1599–607.CrossRefPubMedPubMedCentralGoogle Scholar
  7. Fernandez-Ortega A, Garcia del Muro X, Navarro M, Germa Lluch JR. Adjuvant chemotherapy of non-seminoma stage I gem cell tumors of the testis. Arch Esp Urol. 2000;53:487–90.PubMedGoogle Scholar
  8. Fossa SD, Horwich A, Russel JM. Optimal planning target volume for stage I testicular seminoma: a Medical Research Council randomized trial. J Clin Oncol. 1999;17:1146–54.CrossRefPubMedGoogle Scholar
  9. Fung C, Fossa SD, Beard CJ, et al. Second malignant neoplasms in testicular cancer survivors. J Natl Compr Cancer Netw. 2012;10:545–56.CrossRefGoogle Scholar
  10. Fung C, Fossa SD, Milano MT, et al. Cardiovascular disease mortality after chemotherapy or surgery for testicular nonseminoma: a population-based study. J Clin Oncol. 2015;33:3105–14.CrossRefPubMedPubMedCentralGoogle Scholar
  11. Horwich A, Fossa SD, Huddart R, et al. Second cancer risk and mortality in men treated with radiotherapy for stage I seminoma. Br J Cancer. 2014;110:256–63.CrossRefPubMedGoogle Scholar
  12. Hosni A, Warde P, Jewett M et al. Clinical characteristics and outcomes of late relapse in stage I testicular seminoma, Clin Oncol 2016; 28: 648–654.Google Scholar
  13. Huddart RA, Norman A, Shahidi M, et al. Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol. 2003;21:1513.CrossRefPubMedGoogle Scholar
  14. Jones WG, Fossa SD, Mead GM, et al. Randomized trial of 30 versus 20 Gy in the adjuvant treatment of stage I testicular seminoma: a report on Medical Research Council Trial TE 18, European Organization for the Research and Treatment of cancer Trial 30942. J Clin Oncol. 2005;23:1200.CrossRefPubMedGoogle Scholar
  15. Kero AE, Järvelä LS, Arola M et al. Cardiovascular morbidity in long-term survivors of early-onset cancer: a population-based study, Int J Cancer 2014; 134: 664–673.Google Scholar
  16. Kollmannsberger C, Tandstad T, Bedard PL, et al. Patterns of relapse in patients with clinical stage I testicular cancer managed with active surveillance. J Clin Oncol. 2015;33:51–7.CrossRefPubMedGoogle Scholar
  17. Lewinshtein D, Gulati R, Nelson PS, et al. Incidence of second malignancies after external radiotherapy for clinical stage I testicular seminoma. BJU Int. 2012;109:706–12.CrossRefPubMedGoogle Scholar
  18. Mortensen MS, Lauritsen J, Kier MG, et al. Late relapses in stage I testicular cancer patients on surveillance. Eur Urol. 2016;70:365–71.CrossRefPubMedGoogle Scholar
  19. Oliver RT, Mason MD, Mead GM, et al. Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomized trial. Lancet. 2005;366:293–300.CrossRefPubMedGoogle Scholar
  20. Oliver RT, Mead GM, Rustin GJ, et al. Randomized trial of carboplatin versus radiotherapy for stage I seminoma: mature results on relapse and contralateral testis cancer rates in MRC TE19/EORTC 30982 study. J Clin Oncol. 2011;29:957–62.CrossRefPubMedGoogle Scholar
  21. Tandstad T, Dahl O, Cohn-Cedermark G, et al. Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: the SWENOTECA management program. J Clin Oncol. 2009;27:2122–8.CrossRefPubMedGoogle Scholar
  22. Tandstad T, Smaaland R, Solberg A, et al. Management of seminomatous testicular cancer: a binational prospective population-based study from the Swedish Norwegian testicular cancer study group. J Clin Oncol. 2011;29:719–25.CrossRefPubMedGoogle Scholar
  23. Tandstad T, Stahl O, Hakansson U, et al. One course of adjuvant BEP in clinical stage I nonseminoma mature and expanded results from the SWENOTECA group. Ann Oncol. 2014;25:2167–72.CrossRefPubMedGoogle Scholar
  24. Tandstad T, Stahl O, Dahl O, et al. Treatment of stage I seminoma, with one course of adjuvant carboplatin or surveillance, risk-adapted recommendations implementing patient autonomy: a report from the Swedish and Norwegian Testicular Cancer Group (SWENOTECA). Ann Oncol. 2016;27:1299–304.CrossRefPubMedGoogle Scholar
  25. van den Belt-Dusebout AW, Nuver J, de Wit R, et al. Long-term risk of cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol. 2006;24:467–75.CrossRefPubMedGoogle Scholar
  26. Vidal AD, Thalmann GN, Karamitopoulou-Diamantis E, et al. Long-term outcome of patients with clinical stage I high-risk nonseminomatous germ-cell tumors 15 years after one adjuvant cycle of bleomycin, etoposide, and cisplatin. Ann Oncol. 2015;26:374–7.CrossRefPubMedGoogle Scholar
  27. Warde P, Gospodarowicz MK, Panzarella T, et al. Stage I testicular seminoma: results of adjuvant irradiation and surveillance. J Clin Oncol. 1995;13:2255–62.CrossRefPubMedGoogle Scholar
  28. Warde P, Gospodarowicz MK, Banerjee D, et al. Prognostic factors for relapse in stage I testicular seminoma treated with surveillance. J Urol. 1997;157:1705–10.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Urology, Pediatric Urology and UrooncologyKliniken Essen Mitte, Hyussens-StiftungEssenGermany

Section editors and affiliations

  • Chris Protzel
    • 1
  • Axel Heidenreich
    • 2
  1. 1.Universitätsklinikum Rostock , Urologische Klinik und PoliklinikRostockGermany
  2. 2.Division of Oncological Urology, Department of UrologyUniversity of KölnKölnGermany

Personalised recommendations